Nourianz FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 29, 2019.
Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “OFF” episodes.
Development Timeline for Nourianz
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.